Saltar al contenido
PivotalWire
Domingo 22 nov 2026SEC · NASDAQ biomédico

Calendario›MDWD›EscharEx

EscharEx

Ensayo de MediWound Ltd. en Hard to Heal Wounds · Venous Leg Ulcers · Diabetic Lower Extremity Ulcers · Traumatic/ Post Operative Wounds (del registro, en inglés).

Todo sobre el fármaco: EscharEx.

Fase
Fase 2
Estado
Completado
Participantes
111
previstos
Centros
8
Fin del objetivo primario
dic 2017
fecha real

Título oficial en el registro (en inglés): Efficacy and Safety Study of EscharEx to Treat (Debride) Hard to Heal Wounds

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, doble ciego. Comenzó en jul 2014.

De principio a fin

  1. Empieza el ensayo (jul 2014)
  2. Lectura de resultados dic 2017 (real)
  3. Hoy

Los cambios los anota PivotalWire desde agosto de 2026; lo anterior no lo tenemos. El historial completo, versión a versión, está en ClinicalTrials.gov.

Qué mide

Incidence of complete debridement (non-viable tissue removal) at the end of the debridement period assessed by the blinded assessor by clinical evaluation. (up to 10 treatment days) (del registro, en inglés)

Qué se prueba

Ensayo aleatorizado, multicéntrico y con evaluador ciego, que compara el tratamiento desbridante EscharEx con un gel vehículo en pacientes con heridas difíciles de cicatrizar.

Lo que dice el documentoThis study will be a multi-center, assessor blinded, randomized, controlled study intended to demonstrate superiority of EscharEx debriding treatment over the Gel Vehicle control treatment in patients with hard to heal wounds. 72 + 24 adults with >50% necrotic/slough/fibrin non-viable tissue on a hard to heal wound (venous leg ulcer, diabetic lower extremity ulcer or traumatic/ post operative wound) between 5 cm2 and 200 cm2 (surface area in stage 1) or 3 cm2 - 150 cm2 (in stage 2), will be enrolled into the study.

Traducción automática (claude-haiku-5-5). Lo comprobado es la cita: está literal en el documento y sus cifras cuadran con las de la frase. Todavía no la ha leído una persona.

Cómo lo describe el promotor

En el documentoEn inglés, del registroThe main objective of this study is to assess the safety and the efficacy of EscharEx in preparing the wound's bed in patients with hard to heal venous leg ulcers, diabetic lower extremity ulcers and traumatic/post operative wounds. This study will be a multi-center, assessor blinded, randomized, controlled study intended to demonstrate superiority of EscharEx debriding treatment over the Gel Vehicle control treatment in patients with hard to heal wounds. 72 + 24 adults with >50% necrotic/slough/fibrin non-viable tissue on a hard to heal wound (venous leg ulcer, diabetic lower extremity ulcer or traumatic/ post operative wound) between 5 cm2 and 200 cm2 (surface area in stage 1) or 3 cm2 - 150 cm2 (in stage 2), will be enrolled into the study. Patients will undergo a 1 week screening period (2 visits) which will include: record of demographics, medical history and concomitant medications, vital signs, physical examination, clinical laboratory tests, wound photography and assessments and questionnaires (wound status and quality of life). During this period wounds will be treated by standard treatment per the decision of the physician. During this screening period, subjects whose study wound size (surface area) decreases by more than 20 percent will be excluded. Following completion of the screening process, eligible patients will be randomized to either EscharEx or Gel vehicle debridement treatments. In stage 1 (72 patients): Treatment will be performed for up to 10 applications or until complete debridement is achieved, whichever occurs first. In stage 2 (24 patients): Treatment will be performed for up to 8 applications or until complete debridement is achieved, whichever occurs first. Following each application the wound will be washed, photographed and assessed for wound size, removal of nonviable tissue and change in granulation tissue (by digital planimetry software), wound status, and safety parameters. Subsequent to each debridement treatment the wound will be dressed with moist-to-moist saline gauze (except when successive 24h or 48h treatments are performed, in the second stage). Following completion of the debridement treatment period, patients will be treated according to standard procedures and evaluated (wound assessments) once a week until complete wound closure for up to 12 weeks from last application (up to 12 visits). Only during the first stage of the study, for patients who achieved wound closure, additional 3 monthly (3 visits) follow- up visits of wound closure recurrence will be conducted. Quality of life (QoL) will be evaluated at the last follow-up visit - 3 months post wound closure follow-up period. For patients who didn't achieve wound closure only the 3 months FU visit will be conducted. For patients enrolled at the second stage, if wound closure was achieved at the 12 weeks follow-up, additional visit will be performed 2 weeks later to confirm wound closure.

Sigue a MDWD y recibe cada mañana en tu correo lo que haya presentado ante la SEC, en castellano. Crear una cuenta. ¿Ya tienes cuenta? Entrar.

Más ensayos de MDWD

EnsayoFaseEstadoLectura de resultados
EscharEx 5%Fase 1/2Reclutando pacientesmay 2022 (prevista, ya pasada: sin actualizar en el registro)
EscharEx · VALUEFase 3Reclutando pacientesdic 2026 (prevista)
EX-03Fase 2Aún sin reclutarago 2028 (prevista)
EscharEx · H2HFase 2Aún sin reclutarnov 2028 (prevista)
EscharExFase 2Completadomay 2022 (real)
EscharExFase 2Completadodic 2021 (real)

Todos los de MDWD, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT02020746), actualizada en ago 2018.